JP2010535220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535220A5 JP2010535220A5 JP2010519954A JP2010519954A JP2010535220A5 JP 2010535220 A5 JP2010535220 A5 JP 2010535220A5 JP 2010519954 A JP2010519954 A JP 2010519954A JP 2010519954 A JP2010519954 A JP 2010519954A JP 2010535220 A5 JP2010535220 A5 JP 2010535220A5
- Authority
- JP
- Japan
- Prior art keywords
- antipsychotic
- combination
- olanzapine
- risperidone
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 37
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 33
- 230000000561 anti-psychotic effect Effects 0.000 claims description 32
- 229960005017 olanzapine Drugs 0.000 claims description 24
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 24
- 229960001534 risperidone Drugs 0.000 claims description 24
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 24
- -1 aboperidone Chemical compound 0.000 claims description 23
- 201000000980 schizophrenia Diseases 0.000 claims description 19
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims description 16
- 239000000164 antipsychotic agent Substances 0.000 claims description 14
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 12
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims description 12
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 claims description 12
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 12
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 12
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims description 12
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 claims description 12
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 claims description 12
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims description 12
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims description 12
- 229960003036 amisulpride Drugs 0.000 claims description 12
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 12
- 229960004372 aripiprazole Drugs 0.000 claims description 12
- 229960005245 asenapine Drugs 0.000 claims description 12
- 229950009087 bifeprunox Drugs 0.000 claims description 12
- 229950002871 blonanserin Drugs 0.000 claims description 12
- 229960004170 clozapine Drugs 0.000 claims description 12
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 12
- 229960002464 fluoxetine Drugs 0.000 claims description 12
- 229960003162 iloperidone Drugs 0.000 claims description 12
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 12
- LHAPOGAFBLSJJQ-GUTACTQSSA-N iti007 Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C([C@@H]1N2CCN(C=3C=CC=C(C2=3)[C@@H]1C1)C)CN1CCCC(=O)C1=CC=C(F)C=C1 LHAPOGAFBLSJJQ-GUTACTQSSA-N 0.000 claims description 12
- 229960001432 lurasidone Drugs 0.000 claims description 12
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 12
- 229960001861 melperone Drugs 0.000 claims description 12
- 229950010634 ocaperidone Drugs 0.000 claims description 12
- 229960001057 paliperidone Drugs 0.000 claims description 12
- 229950004193 perospirone Drugs 0.000 claims description 12
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 claims description 12
- 229960004431 quetiapine Drugs 0.000 claims description 12
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 12
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 12
- 229940034173 symbyax Drugs 0.000 claims description 12
- 229960000607 ziprasidone Drugs 0.000 claims description 12
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 12
- 229960004496 zotepine Drugs 0.000 claims description 12
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229940005529 antipsychotics Drugs 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 230000007370 cognitive improvement Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 238000002648 combination therapy Methods 0.000 description 6
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 229960000762 perphenazine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 229960001374 fluphenazine decanoate Drugs 0.000 description 2
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 229960000652 sertindole Drugs 0.000 description 2
- 229960005013 tiotixene Drugs 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- BXDAOUXDMHXPDI-UHFFFAOYSA-N trifluoperazine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 BXDAOUXDMHXPDI-UHFFFAOYSA-N 0.000 description 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 2
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007129567/15A RU2508106C2 (ru) | 2007-08-01 | 2007-08-01 | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии |
| RU2007129568/15A RU2508096C2 (ru) | 2007-08-01 | 2007-08-01 | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии |
| PCT/US2008/009357 WO2009017836A1 (en) | 2007-08-01 | 2008-08-01 | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010535220A JP2010535220A (ja) | 2010-11-18 |
| JP2010535220A5 true JP2010535220A5 (https=) | 2011-09-15 |
Family
ID=40304696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519954A Pending JP2010535220A (ja) | 2007-08-01 | 2008-08-01 | 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110269777A1 (https=) |
| EP (1) | EP2175724A4 (https=) |
| JP (1) | JP2010535220A (https=) |
| KR (1) | KR20100054812A (https=) |
| CN (1) | CN101842010A (https=) |
| AU (1) | AU2008282742A1 (https=) |
| BR (1) | BRPI0815850A2 (https=) |
| CA (1) | CA2719824A1 (https=) |
| MX (1) | MX2010001218A (https=) |
| WO (1) | WO2009017836A1 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7837812B2 (en) | 2004-05-21 | 2010-11-23 | Ati Properties, Inc. | Metastable beta-titanium alloys and methods of processing the same by direct aging |
| AU2008302751A1 (en) | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN102046625B (zh) | 2008-03-24 | 2015-04-08 | 梅迪维新技术公司 | 桥连杂环化合物及其使用方法 |
| TWI443098B (zh) | 2008-03-24 | 2014-07-01 | Medivation Technologies Inc | 吡啶并〔３，４－ｂ〕吲哚及使用方法 |
| CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| AU2009308706C1 (en) | 2008-10-31 | 2016-01-21 | Medivation Technologies, Inc. | Pyrido (4,3-b) indoles containing rigid moieties |
| WO2010051503A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
| KR20110132564A (ko) | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| EP2581374B1 (en) * | 2009-04-10 | 2014-03-19 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Preparation of tetrahydropyrido[4,3-b]indole derivatives |
| CA2760541A1 (en) * | 2009-04-29 | 2010-11-04 | Medivation Technologies, Inc. | Pyrido[4,3-b] indoles and methods of use |
| JP5827943B2 (ja) | 2009-04-29 | 2015-12-02 | メディベイション テクノロジーズ， インコーポレイテッド | ピリド［４，３−ｂ］インドールおよびその使用方法 |
| WO2011038163A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
| AU2010298169B2 (en) | 2009-09-23 | 2015-10-29 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
| EP2480078A4 (en) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | PYRIDO- [4,3-B] INDOLE AND USE METHOD THEREFOR |
| WO2011103485A1 (en) * | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103448A1 (en) * | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| JP6138491B2 (ja) | 2010-02-24 | 2017-05-31 | ザ ブロード インスティテュート， インコーポレイテッド | 感染性疾患の病原体およびそれらの薬剤感受性を診断する方法 |
| CN103476417A (zh) | 2011-02-18 | 2013-12-25 | 梅迪维新技术公司 | 治疗糖尿病的化合物和方法 |
| US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2014128882A1 (ja) * | 2013-02-21 | 2014-08-28 | 医療法人 和楽会 | 不安うつ病の治療薬 |
| WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| HUE053159T2 (hu) | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
| IL305990B2 (en) | 2013-12-03 | 2025-12-01 | Intra Cellular Therapies Inc | Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder |
| MX365969B (es) | 2014-04-04 | 2019-06-21 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| KR101646962B1 (ko) | 2014-09-29 | 2016-08-10 | 한국과학기술연구원 | CaM 저해활성을 가지는 페노싸이아진 유도체 |
| US20160184290A1 (en) * | 2014-12-31 | 2016-06-30 | Paul J. Markovitz | Method of treating schizophrenia |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| WO2016205631A1 (en) * | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
| CN108883111B (zh) | 2016-01-26 | 2021-10-08 | 细胞内治疗公司 | 有机化合物 |
| PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| KR102793584B1 (ko) | 2016-12-31 | 2025-04-09 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 불안의 치료를 위한 설하 덱스메데토미딘의 용도 |
| IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| US10035795B1 (en) | 2017-04-06 | 2018-07-31 | Korea Institute Of Science And Technology | Phenothiazine derivatives having CaM inhibitory activity |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| JP7223742B2 (ja) | 2017-07-26 | 2023-02-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| CN111107847A (zh) | 2017-09-26 | 2020-05-05 | 细胞内治疗公司 | 新的盐和晶体 |
| WO2019128991A1 (en) * | 2017-12-26 | 2019-07-04 | Sunshine Lake Pharma Co., Ltd. | Lurasidone solid dispersion and preparation method thereof |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IL321985A (en) | 2018-06-06 | 2025-09-01 | Intra Cellular Therapies Inc | New salts and crystals |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| PL3813802T3 (pl) | 2018-06-27 | 2025-04-22 | Bioxcel Therapeutics, Inc. | Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania |
| EP3843729A4 (en) | 2018-08-29 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND PROCESSES |
| CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12195463B2 (en) | 2018-12-21 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7673040B2 (ja) | 2019-07-07 | 2025-05-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| EP3999058A4 (en) | 2019-07-19 | 2023-05-03 | Bioxcel Therapeutics, Inc. | NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC CONNECTION |
| TW202302094A (zh) * | 2021-02-26 | 2023-01-16 | 美商百歐克斯賽爾治療公司 | 用於治療激躁之方法及組合物 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| CN115290775A (zh) * | 2022-07-25 | 2022-11-04 | 上海市徐汇区中心医院 | 一种精神类药物质控品、其试剂盒、制备方法及应用 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS229067B1 (en) * | 1981-08-20 | 1984-04-16 | Svorad Stolc | Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof |
| US4672117A (en) * | 1985-09-16 | 1987-06-09 | American Home Products Corporation | Antipsychotic gamma-carbolines |
| US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| US5631265A (en) * | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| TW470745B (en) * | 1996-05-23 | 2002-01-01 | Janssen Pharmaceutica Nv | Hexahydro-pyrido[4,3-b]indole derivatives |
| US6849640B2 (en) * | 2001-08-08 | 2005-02-01 | Pharmacia & Upjohn Company | Therapeutic 1H-pyrido [4,3-b] indoles |
| WO2005120463A1 (en) * | 2004-06-09 | 2005-12-22 | Ranbaxy Laboratories Limited | Rapidly disintegrating tablets of risperidone |
| WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| JP2010528016A (ja) * | 2007-05-25 | 2010-08-19 | メディベーション ニューロロジー， インコーポレイテッド | 細胞を刺激するための方法および組成物 |
-
2008
- 2008-08-01 WO PCT/US2008/009357 patent/WO2009017836A1/en not_active Ceased
- 2008-08-01 CA CA2719824A patent/CA2719824A1/en not_active Abandoned
- 2008-08-01 BR BRPI0815850-9A2A patent/BRPI0815850A2/pt not_active IP Right Cessation
- 2008-08-01 US US12/671,679 patent/US20110269777A1/en not_active Abandoned
- 2008-08-01 EP EP08826868A patent/EP2175724A4/en not_active Withdrawn
- 2008-08-01 JP JP2010519954A patent/JP2010535220A/ja active Pending
- 2008-08-01 AU AU2008282742A patent/AU2008282742A1/en not_active Abandoned
- 2008-08-01 MX MX2010001218A patent/MX2010001218A/es not_active Application Discontinuation
- 2008-08-01 CN CN200880107277A patent/CN101842010A/zh active Pending
- 2008-08-01 KR KR1020107004429A patent/KR20100054812A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535220A5 (https=) | ||
| TWI638654B (zh) | 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物 | |
| CN105873576A (zh) | 治疗肥胖 | |
| JP2018523689A5 (https=) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| CN108697678A (zh) | sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用 | |
| Fong et al. | Repurposing chloroquine analogs as an adjuvant cancer therapy | |
| Chave et al. | Henoch‐Schönlein purpura following hepatitis B vaccination | |
| CN105163806A (zh) | 左西替利嗪和孟鲁司特在治疗过敏反应中的用途 | |
| JP2008526927A5 (https=) | ||
| US20200306235A1 (en) | Compositions and methods for treating rheumatoid arthritis | |
| JP2013500943A5 (https=) | ||
| EP3119388A1 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| AU2022201030B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
| JP5089687B2 (ja) | アルコール依存症または薬物依存症の予防または治療剤 | |
| US20090163544A1 (en) | Use of NK-3 Receptor Antagonists for the Treatment of Nausea and Vomiting | |
| US20170020867A1 (en) | Use of masitinib for the treatment of crohn's disease | |
| BRPI0510855A (pt) | medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis | |
| EP1667719A1 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| CN110891574A (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| CN108478581A (zh) | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 | |
| HK40041658A (en) | Benzoic acid or a salt thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
| JP2006516267A5 (https=) |